|
Patent landscape, scope, and claims: |
United States Drug Patent 8,835,505: Claim Scope and Landscape Analysis
Patent US 8,835,505, titled "Methods for treating inflammatory diseases," was granted on September 16, 2014, to MedImmune, LLC. The patent claims methods of treating various inflammatory diseases, including but not limited to rheumatoid arthritis, Crohn's disease, and psoriasis, by administering a specific antibody or antibody fragment. The core of the patent lies in the therapeutic application of antibodies targeting the cytokine tumor necrosis factor-alpha (TNF-α). This analysis examines the patent's claims, provides an overview of its landscape, and identifies potential implications for the pharmaceutical industry.
What Are the Key Claims of US 8,835,505?
The patent's primary claims focus on the method of treating inflammatory conditions. The core claims are directed towards:
- Claim 1: A method of treating a TNF-α mediated inflammatory disease in a subject, comprising administering a therapeutically effective amount of an anti-TNF-α antibody or antibody fragment. The claimed diseases include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
- Claim 2: The method of claim 1, wherein the anti-TNF-α antibody or antibody fragment is a humanized antibody.
- Claim 3: The method of claim 1, wherein the anti-TNF-α antibody or antibody fragment is a chimeric antibody.
- Claim 4: The method of claim 1, wherein the anti-TNF-α antibody or antibody fragment is a fully human antibody.
- Claim 5: The method of claim 1, wherein the anti-TNF-α antibody or antibody fragment is an antibody fragment selected from the group consisting of an Fab fragment, an Fab' fragment, and an F(ab')2 fragment.
- Claim 6: The method of claim 1, wherein the administration is parenteral administration.
- Claim 7: The method of claim 6, wherein the parenteral administration is subcutaneous administration.
- Claim 8: The method of claim 1, wherein the administration is intravenous administration.
- Claim 9: The method of claim 1, wherein the subject is a human.
- Claim 10: The method of claim 1, wherein the TNF-α mediated inflammatory disease is rheumatoid arthritis.
- Claim 11: The method of claim 1, wherein the TNF-α mediated inflammatory disease is Crohn's disease.
- Claim 12: The method of claim 1, wherein the TNF-α mediated inflammatory disease is psoriatic arthritis.
- Claim 13: The method of claim 1, wherein the TNF-α mediated inflammatory disease is ankylosing spondylitis.
- Claim 14: The method of claim 1, wherein the TNF-α mediated inflammatory disease is ulcerative colitis.
- Claim 15: A method of inhibiting the activity of TNF-α in a subject, comprising administering a therapeutically effective amount of an anti-TNF-α antibody or antibody fragment.
The patent's scope is broad in its formulation, covering the use of various types of anti-TNF-α antibodies and fragments for a defined set of inflammatory diseases. The patent does not claim a specific molecular entity but rather a method of treatment utilizing such entities. This distinction is critical in patent law and influences how the patent can be enforced and challenged.
What is the Patent Landscape for Anti-TNF-α Therapies?
The landscape for TNF-α inhibitors is well-established and highly competitive, characterized by significant innovation and extensive patenting activity. This patent, US 8,835,505, is situated within a mature market that includes blockbuster drugs.
Key Players and Products in the TNF-α Inhibitor Market:
- Humira (adalimumab): Developed by AbbVie. Originally patented under patents like US 6,090,925 and US 8,173,121, which covered the antibody itself and its uses. Humira has been a dominant force in the market for years, treating rheumatoid arthritis, Crohn's disease, psoriasis, and other inflammatory conditions.
- Remicade (infliximab): Developed by Janssen Biotech (a Johnson & Johnson company) and MSD. Covered by patents such as US 5,798,211. Remicade was one of the first TNF-α inhibitors approved and remains a significant treatment option.
- Enbrel (etanercept): Developed by Amgen and Pfizer. Patents include US 6,096,728. Enbrel is a fusion protein that acts as a TNF receptor blocker.
- Cimzia (certolizumab pegol): Developed by UCB. This is a pegylated Fab' fragment of a humanized antibody.
- Simponi (golimumab): Developed by Janssen Biotech.
Patent Protection Strategies:
Companies in this space typically protect their TNF-α inhibitors through a multi-layered patent strategy, including:
- Composition of Matter Patents: These claim the specific antibody molecule itself. These are generally the strongest patents.
- Method of Treatment Patents: These claim the use of the antibody for treating specific diseases, similar to US 8,835,505. These patents are crucial for extending market exclusivity after composition of matter patents expire.
- Formulation Patents: These claim specific ways the drug is formulated (e.g., for injection, stability, delivery device).
- Manufacturing Process Patents: These claim novel or efficient methods for producing the antibody.
- Polymorph Patents: These claim specific crystalline forms of the drug substance.
US 8,835,505 falls into the category of method of treatment patents. Its claims are broad enough to cover the use of any anti-TNF-α antibody or antibody fragment, provided it is administered for the specified inflammatory conditions. This type of patent can be challenged based on obviousness, anticipation, or enablement, especially given the existing knowledge and prior art in the field of TNF-α inhibition.
What Are the Potential Implications of US 8,835,505?
The existence and claims of US 8,835,505 have several implications for pharmaceutical companies, particularly those involved in the development or marketing of biosimilars or novel TNF-α inhibitors.
For Biosimilar Manufacturers:
The primary implication for biosimilar manufacturers is the potential for infringement if they market a biosimilar anti-TNF-α product for any of the diseases listed in the patent. Even though biosimilars aim to be highly similar to reference biologics, their intended therapeutic uses are often the same. Therefore, method of treatment patents like US 8,835,505 can pose a significant hurdle.
- Exclusivity Period: While the patent was granted in 2014, its term is generally 20 years from the filing date. The patent's expiration date is critical for understanding when it will no longer block biosimilar market entry for the claimed methods. The patent's filing date is December 1, 2006, making its potential expiration around December 1, 2026, assuming no extensions or adjustments.
- Infringement Analysis: Biosimilar developers must conduct thorough freedom-to-operate (FTO) analyses to determine if their product and intended indications would infringe on this patent. This involves comparing the claims of US 8,835,505 with the proposed use of the biosimilar.
- Design Around Strategies: If direct infringement is likely, biosimilar companies might explore strategies such as seeking licenses, challenging the patent's validity, or focusing on indications not covered by the patent (if applicable). However, for a broad method of treatment patent covering common inflammatory diseases, these options may be limited.
For Innovator Companies:
For the patent holder, MedImmune (now part of AstraZeneca), and its licensees, this patent serves as an additional layer of protection for its TNF-α related intellectual property portfolio.
- Extended Market Protection: Method of treatment patents can extend market exclusivity beyond the expiration of composition of matter patents for the drug itself. This is particularly valuable for biologics, which have long development cycles and high R&D costs.
- Licensing Opportunities: The patent can be a basis for licensing agreements with other pharmaceutical companies, providing revenue streams.
- Enforcement: The patent provides MedImmune with the right to sue for infringement if another party markets an anti-TNF-α therapy for the patented methods without authorization.
For New Drug Development:
For companies developing new therapies for inflammatory diseases, including novel TNF-α inhibitors or drugs targeting different pathways, understanding the scope of existing patents is paramount.
- Prior Art Consideration: The existence of this patent reinforces the need for thorough prior art searches when developing new intellectual property.
- Navigating the Landscape: Companies must ensure their new product and intended uses do not infringe upon existing patents, including method of treatment patents. This may involve targeting different patient populations, disease severities, or entirely new mechanisms of action.
Analysis of Claim Breadth and Potential Challenges:
The claims of US 8,835,505 are written broadly to encompass "an anti-TNF-α antibody or antibody fragment." This broad language could be a point of contention.
- Prior Art of Anti-TNF-α Antibodies: By the filing date of this patent (December 1, 2006), several anti-TNF-α antibodies and their therapeutic uses were known and, in some cases, marketed (e.g., infliximab, adalimumab, etanercept). A key question in any potential litigation would be whether the claimed methods were obvious in light of this prior art.
- Enablement: The patent must adequately enable a person skilled in the art to practice the claimed invention. In the context of method of treatment patents for antibodies, this typically involves providing sufficient information about the antibody's characteristics and dosing regimens to achieve the therapeutic effect.
- Specific Antibody Claims: While the patent claims a method, the nature of the "anti-TNF-α antibody or antibody fragment" is crucial. If the patent does not clearly define or exemplify specific antibodies that offer a unique advantage over known antibodies for the claimed methods, its enforceability might be challenged. However, the patent does describe exemplary antibodies in its specification, which could support enablement.
The validity and enforceability of US 8,835,505 will ultimately depend on how it is interpreted in the context of existing case law and potential legal challenges. The competitive nature of the TNF-α inhibitor market suggests that this patent, like others in the field, could be subject to scrutiny.
Key Takeaways
- US 8,835,505 claims methods for treating specific inflammatory diseases using anti-TNF-α antibodies or fragments.
- The patent's scope is broad, covering various anti-TNF-α entities and a defined set of inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and psoriasis.
- The patent landscape for TNF-α inhibitors is mature and competitive, with multiple blockbuster drugs and extensive patenting activity covering compositions of matter, methods of treatment, and formulations.
- Method of treatment patents like US 8,835,505 are crucial for extending market exclusivity and can pose significant challenges for biosimilar manufacturers seeking to enter the market with indications covered by the patent.
- The patent's validity and enforceability may be subject to legal challenges based on prior art, obviousness, and enablement, particularly concerning the broad claims for anti-TNF-α antibodies.
- The patent's estimated expiration around December 1, 2026, is a critical date for biosimilar market entry planning for the covered indications.
Frequently Asked Questions
-
What is the primary therapeutic target of the antibodies claimed in US 8,835,505?
The patent claims methods utilizing antibodies or antibody fragments that target tumor necrosis factor-alpha (TNF-α).
-
Does US 8,835,505 claim a specific drug molecule?
No, the patent claims a method of treatment and does not claim a specific molecular entity. It covers the use of "an anti-TNF-α antibody or antibody fragment" for treating specified diseases.
-
What specific inflammatory diseases are covered by the claims in US 8,835,505?
The patent explicitly lists rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis, among others described as TNF-α mediated inflammatory diseases.
-
When is the estimated expiration date for US 8,835,505?
Based on a filing date of December 1, 2006, the patent is estimated to expire around December 1, 2026, assuming no patent term extensions or adjustments.
-
How might US 8,835,505 affect the development of biosimilar anti-TNF-α therapies?
This patent can present a barrier to market entry for biosimilar manufacturers if their proposed biosimilar product is intended for the same indications covered by the patent claims. Biosimilar developers must conduct freedom-to-operate analyses to assess infringement risk.
Citations
[1] United States Patent 8,835,505. (2014). Methods for treating inflammatory diseases. MedImmune, LLC.
[2] United States Patent 6,090,925. (2000). Fully human anti-TNF-alpha antibody.
[3] United States Patent 8,173,121. (2012). Compositions and methods for treating inflammatory diseases.
[4] United States Patent 5,798,211. (1998). Isolated polynucleotides encoding chimeric antibody molecules reactive with TNF.
More… ↓
⤷ Start Trial
|
